Jynneos mpox vaccine now commercially available ahead of Pride Month

In a strategic move that spotlights the commitment to public health and the well-being of at-risk communities, the Jynneos vaccine, developed by Bavarian Nordic, became commercially available Monday. This significant step forward follows the conclusion of the mpox public health emergency in January 2023 and aims to ensure broad accessibility of the vaccine, particularly as the nation approaches Pride Month — a period of vibrant celebration and gathering within the LGBTQ+ community that has historically contributed to the spread of the virus in the U.S.

Lee Ann Kimak, the U.S. commercial lead of Bavarian Nordic, the vaccine manufacturer, stressed the company’s efforts in an interview with The Advocate.

Related: CDC Greenlights Routine Mpox Vaccination for Those Most at Risk

“We wanted to get ahead of Pride events,” she said. “We have worked with the top pharmacies here in the U.S. to make sure that product will be available.” Kimak highlighted that insurance should cover the cost of the vaccine, and she pointed to support for the underinsured, ensuring that no one is left behind in the vaccination effort.

North American medical director for Bavarian Nordic, Peter Costa, clarified the vaccine’s administration method and efficacy.

Moving away from the emergency use authorization’s intradermal injections, Jynneos is now administered as two subcutaneous doses, aligning with its original Food and Drug Administration-approved method. “This is a two-dose subcutaneous administration,” Costa said. In October, the Centers for Disease Control and Prevention approved routine vaccination for mpox using the Jynneos product.

Trending stories

Elon Musk deadnames his 'killed' child — his trans daughter claps back

How climate disasters hurt mental health in young people

Exclusive: Mike Maimone honors late husband Howard Bragman in new single “On My Way”

SFAF's Dr. Tyler TerMeer says he'll continue to fight for health care for all

Gerald Garth is determined to keep people of color happy and healthy through trying times

BREAKING NEWS: Trump admin moves to end federal HIV prevention programs

Discover why chic Costa Navarino is Europe's luxury getaway

'White Lotus' S3 E6 recap: We need to talk about the incest storyline

Pride journey Walla Walla: An LGBTQ+ wine, food, and adventure getaway

Trump's orders prompt CDC to erase HIV resources

Kelly Marie Tran says all of her roles are queer — including her latest in 'Control Freak'

10 lesbian sports movies that are total game-changers

Lana Ja'Rae was the ingenue of 'Drag Race' S17. Why are you mad, sis?

All 6 rogue Mississippi cops got long prison sentences in 'Goon Squad' torture of 2 Black men

Elon Musk uses burner accounts on X, doesn’t fact-check: report

France becomes world’s first country to enshrine abortion rights in constitution

Lexi Love goes public with HIV status after Trump wipes resources from federal website

Vivian Wilson calls father Elon Musk a 'pathetic manchild' in new tell-all interview

11 hypocritical MAGA politicians and supporters accused of sexual harassment and assault

Suzie Toot says the 'RuPaul's Drag Race' cast 'got hate crimed' in Las Vegas

Yellowjackets' Liv Hewson: Breaking Hollywood's binary is 'doable'

Where to stay in LGBTQ+ Ireland: Castles, domes and luxury retreats

From rock legends to Pride flags: Discover the vibrant LGBTQ+ scene in Asbury Park

How RuPaul dragified Las Vegas with a triumphant comeback

Joe Biden has tied the record for most LGBTQ+ judges confirmed in federal courts

• 0
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8

“The intradermal recommendation was largely made because of the, at the time, dose-sparing recommendation,” Costa explained. He emphasized the vaccine’s effectiveness, noting, “The current published data suggests the vaccine effectiveness from 66 percent to 89 percent following two doses.”

Related: Mpox Is Almost Gone in the US, Leaving Lessons & Mysteries Behind

Costa also spoke about the significance of the vaccine for the LGBTQ+ community, especially in light of the upcoming Pride Month. “According to the most recent [Advisory Committee on Immunization Practices] recommendations, the guidance [for who should get the vaccine] follows from the height of the outbreak. So, I always say while anybody can get mpox, most cases in the United States, and the recommendation is for gay and bisexual men who have sex with men as well as transgender or nonbinary persons that have other risk factors.”

As discussions about vaccine safety and public trust continue, he added that it’s crucial to recognize that Jynneos is not a new player in the field of vaccines. “I would want everybody to know that this vaccine has been studied for over 20 years and in over 20 clinical trials,” Costa said. He emphasized the vaccine’s nonreplicating nature and its comprehensive safety profile compared to previous smallpox vaccines, underlining that Jynneos does not carry the same risk of adverse effects associated with older vaccines.